Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients

Infection Control and Hospital Epidemiology

Volumn 28, Issue 3, 2007, Pages 331-336

  Levin, Phillip D ^a,c   Fowler, Robert A ^a,b   Guest, Cameron ^a,b   Sibbald, William J ^a,b   Kiss, Alex ^a   Simor, Andrew E ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COMORBIDITY; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; HUMAN EXPERIMENT; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; NONHUMAN; TERTIARY HEALTH CARE;

ADULT; AGED; ANTI-INFECTIVE AGENTS; CANADA; CIPROFLOXACIN; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; RISK FACTORS;

EID: 33947601360     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/511701     Document Type: Article

References (34)

1. Fridkin SK, Steward CD, Edwards J, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-252.
2. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24:211-215.
3. NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from lanuary 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485.
4. Bryce EA, Smith JA. Focused microbiological surveillance and gram-negative β-lactamase-mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol 1995; 16:331-334.
5. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp from intensive care units in Europe. J Antimicrob Chemother 1996; 38:409-424.
6. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-888.
7. Hanberger H, Garcia-Rodriguez J-A, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999; 281:67-71.
8. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314.
9. Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-1132.
10. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004; 17:309-316.
11. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38:655-662.
12. WHO Collaborating Centre for Drug Statistics Methodology Web site. Available at: http://www.whocc.no/atcddd/. Accessed January 18, 2007.
13. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140.
14. Papia G, Louie M, Tralla A, et al. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to hospital: is it cost-effective? Infect Control Hosp Epidemiol 1999; 20:473-477.
15. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staph ylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-386.
16. Clinical and Laboratory Standards Institute / NCCLS. Performance Stan dards for Antimicrobial Susceptibility Testing; Fifteenth Informational Sup plement. CLSI/NCCLS document M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
17. Cheong H-J, Yoo C-W, Sohn J-W, et al. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001; 33:48-53.
18. Gentry C, Flournoy DJ, Reinert R. Analysis of antimicrobial resistance among gram-negative bacilli and antimicrobial use in intensive care unit patients for 5 years in a Veterans Affairs medical center. Am J Infect Control 2002; 30:411-416.
19. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37:1643-1648.
20. MacDougall C, Harpe SE, Powell JP, et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005; 11:1197-1204.
21. Aubert G, Carricajo A, Vautrin A-C, et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 2005; 59:83-89.
22. Polk RE, Johnson CK, McClish D, et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39:497-503.
23. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-478.
24. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneu moniae infections. Arch Intern Med 2002; 162:2469-2477.
25. Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-non- susceptible Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:441-449.
26. Muder RR, Brennen C, Goetz AM, et al. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991; 35:256-258.
27. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-1382.
28. Richard P, Delangle M-H, Merrien D, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994; 19:54-59.
29. El Amari EB, Chamot E, Auckenthaler R, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudo monas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33:1859-1864.
30. Harbarth S, Harris AD, Carmeli Y, et al. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001; 33:1462-1468.
31. Huotari K, Tarkka E, Valtonen V, et al. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003; 22:492-495.
32. Gilbert DN, Kohlhepp SJ, Slama KA, et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001; 45:883-892.
33. Ortiz J, Vila MC, Soriano G, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29:1064-1069.
34. Lautenbach E, Metlay JP, Bilker WB, et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41:923-929.